Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
Status:
Recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This is a phase 3 study designed to evaluate whether the administration of ganciclovir
increases ventilator-free days in immunocompetent patients with sepsis associated acute
respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical
illness will effectively suppress CMV reactivation in CMV seropositive adults with
sepsis-associated acute respiratory failure thereby leading to improved clinical outcomes